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INTRODUCTION
Degenerative joint disease is a major cause of di-
minished athletic function and wastage in performance
horses (Frisbie 2005; Jeffcott et al. 1982; McIlwraith
1982). Ideally, all treatment should be based upon a
good knowledge of the anatomy and physiology of the
normal joints and the processes occurring during de-
generation and repair (Goodrich and Nixon 2006;
McIlwraith and Vachon 1988; Nizolek and White
1981). Initially, such treatment should include some de-
gree of rest or exercise restriction. Medical treatments
for DJD may include anti-inflammatory and analgesic
drugs to reduce inflammation and pain, and so-called
disease modifying drugs, such as glucosamine or chon-
droitin sulphate or hyaluronic acid (Goodrich and
Nixon 2006; Malone 2002; Nizolek and White 1981).
In the presence of severe cartilage and bone changes,
the use of articular cartilage curettage, osteophyte re-
moval and even arthrodesis could be suitable in some
cases (Malone 2002; Zubrod and Schneider 2005).
Nevertheless, the aforementioned therapies are me-
rely palliative or may aim at an enhanced repair, albeit
without actual regeneration of the affected joint. Over
the last decades, the field of equine regenerative me-
dicine has been getting increased attention and the use
of stem cells to treat joint pathologies appears to be a
promising strategy to regenerate injured tissues by dif-
ferentiation towards cells with a hyaline-like cartilage
morphology and which are able to produce cartilage-
specific components, such as collagen type II and gly-
cosaminoglycans (Berg et al. 2009; Koch and Betts
2007).
Stem cells are defined as cells displaying a self-re-
newal capacity either with or without differentiation,
depending on the symmetry of the division (Donovan
and Gearhart 2001). More specifically, MSC are adult
stem cells derived from the mesodermal germ layer.
Current clinical regenerative therapies with MSC in
horses mainly use bone marrow (BM)-derived MSC
for the treatment of tendinopathies (Crovace et al.
2007; Smith 2006, 2008; Smith et al. 2003; Violini et
al. 2009) and BM- or adipose tissue (AT)-derived MSC
for the treatment of osteoarthritis (Frisbie et al. 2009).
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ABSTRACT
A 5-year-old German Warmblood stallion with chronic lameness, attributable to degenerative joint disease
(DJD) of the pastern joint unresponsive to medical treatments, was treated with autologous mesenchymal
stem cells (MSC). These MSC were isolated from the peripheral blood (PB) of the patient and injected into
the pastern joint, at a concentration of 2.5x106 cells, twice with an 8-week interval. The positive response to
this stem cell treatment was documented by visual gait evaluation as well as objective pressure plate analyses.
This paper is the first to describe the use of autologous PB-derived MSC to treat a horse suffering from chronic
DJD. The favorable outcome of this single case may stimulate further research on the use of equine peripheral
blood as a source of autologous MSC in equine regenerative medicine.
SAMENVATTING
Een vijfjarige Duitse warmbloedhengst die chronisch mank was ten gevolge van een degeneratieve aandoening
in het kroongewricht en die geen verbetering vertoonde na conservatieve therapieën, werd behandeld met autologe
mesenchymale stamcellen (MSC). Deze MSC werden geïsoleerd uit het perifeer bloed van de patiënt en 2,5 miljoen
van deze cellen werden in het gewricht geïnjecteerd, tweemaal met een interval van acht weken. De positieve evolutie
na behandeling werd gedocumenteerd aan de hand van een klinische evaluatie en objectieve drukplaatanalysen.
In dit artikel wordt voor de eerste maal het gebruik van perifeer bloed beschreven als bron van MSC voor het
behandelen van een degeneratieve gewrichtsaandoening bij een paard.
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In general, obtaining BM and AT samples is invasive
and they are quite difficult to harvest. As an alternative,
scientists have suggested umbilical cord blood (UCB),
which, in humans, can be easily collected at birth.
However, in horses, autologous UCB is not always
available and a sterile collection is only possible under
highly hygienic circumstances, which is difficult to
achieve under field circumstances. The disadvantages
of UCB can be avoided by using peripheral blood (PB)
as a source for MSC. Since the collection of a sterile
blood sample can easily be performed by any equine
practitioner, PB is a readily accessible source of au-
tologous MSC when injuries occur. 
This paper is the first to describe the use of autolo-
gous PB-derived MSC to treat a horse suffering from
chronic lameness attributable to DJD.
CASE HISTORY
One year before the injection of autologous PB-de-
rived MSC, a 5-year-old German Warmblood stallion
was presented with severe unilateral forelimb lameness,
attributable to DJD of the pastern joint. The diagnosis
was made based on clinical and radiographic examina-
tion and a positive response to intra-articular anesthe-
sia. Dorsopalmar and lateromedial radiographs revealed
periarticular new bone formation (Figure 1). Initial
medical treatment with oral non-steroidal anti-inflam-
matory drugs and box rest during two months, and sub-
sequently the intra-articular administration of steroidal
anti-inflammatory medication and hyaluronic acid did
not improve the impaired locomotion. Two months
later, an additional period of one month of complete box
rest and limited movement in a small paddock for the
following five months did not show any improvement
of the lameness. Given the lack of response to therapy
after almost one year, the owners opted for treatment
with autologous PB-derived MSC. The ethical com-
mittee of the Faculty of Veterinary Medicine, Ghent
University, Belgium (EC2010-147) approved the ex-
perimental design.
TREATMENT
Ten mL of blood was taken from the vena jugularis
of the patient and centrifuged at 1000 xg for 20 min-
utes at room temperature (RT). The buffy coat fraction
was collected and diluted 1:1 with phosphate buffered
saline (PBS). Subsequently, the cell suspension was
gently layered on a Percoll gradient (density 1.080
g/mL; GE Healthcare) and centrifuged at 600 xg for 15
minutes at RT. The MSC were maintained and charac-
terized by the presence or absence of different im-
munophenotypic markers and by in vitro differentiation
towards osteoblasts, chondroblasts and adipocytes as
previously described (De Schauwer et al. 2011).
For the first intra-articular injection, 2.5x106 auto-
logous PB-derived MSC of passage 1 (P1) were resus-
pended in 2.5 mL of sterile PBS with 50 µg/mL gen-
tamicin (Sigma-Aldrich, Bornem, Antwerp, Belgium)
and injected into the pastern joint of the patient. A si-
milar injection was repeated eight weeks later with
cryopreserved MSC of P1, which were further cul-
tured up to P3. The intra-articular injections were
performed after the clipping and aseptic preparation
of the skin, as is routinely done before an intra-arti-
cular treatment is started.
Figure 2 gives an overview of the timing of the in-
jections with the autologous PB-derived MSC and all
evaluations of the patient, as described below. 
OUTCOME
Clinical assessment
Clinical evaluation was performed four weeks be-
fore injection (T1), and at 4-week-intervals after the
first injection (T1= 4 weeks, T2= 8 weeks, T3= 12
weeks and T4= 16 weeks), according to the scoring sys-
tem of the American Association of Equine Practitio-
ners (AAEP) by the same team of veterinarians:  grade
0 corresponds to soundness and grade 5 to non-weight-
bearing lameness. At every time point, flexion tests of
the affected lower limb were performed and the results
were graded from 0 (no response) to 3 (severe lame-
ness).
Four weeks before the first injection (T-1), the la-
Figure 1. Dorsopalmar (A) and lateromedial (B) radi-
ographic images of the pastern joint. The images on the
left are weight-bearing and on the right using the
podoblock. The white arrows indicate the periarticular
new bone formation.
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meness was evaluated and localized in the pastern
joint using intra-articular anesthesia. A score of 4/5 was
given, which implied that the horse showed severe la-
meness at the walk and the trot in a straight line, with
a marked head nod and shortened stride. Moreover, the
flexion test of the distal limb was strongly positive
(3/3). Two days after the first injection with the auto-
logous MSC, a mild diffuse swelling was observed at
the pastern. This swelling disappeared within a day. Af-
ter three days of box rest, gradual hand-walking was
initiated. Four weeks after the first injection (T1), the
lameness was obviously decreased, although it could
still be observed consistently at the trot under all cir-
cumstances tested. Therefore, a score of 3/5 was given.
The flexion test at that time point was only slightly po-
sitive (1/3). After the second MSC injection, a mild, lo-
calized swelling together with a mild, transient lame-
ness was observed at the walk. At all subsequent
evaluation time points (T2, T3 and T4), only a residual
irregularity at the trot could be noticed when lunging
the horse (grade 2/5) and the flexion tests were nega-
tive (0/3).
Pressure plate analysis
Recently, pressure plate analysis has been proposed
as a useful tool to quantify equine locomotion and to
evaluate the effects of a therapy in horses (Oosterlinck
et al. 2010a; Oosterlinck et al. 2010b). Indeed, this
technique allows simultaneous analyses of different
limbs and provides detailed information on the loading
of the different portions of the foot during a complete
stance period. In this case, the horse was walked and
trotted over a pressure plate (RSscan 3D 2m-system,
RSscan International, Olen, Belgium) in a custom-
made walkway, as described previously (Oosterlinck et
al. 2010a; Oosterlinck et al. 2010b). A trial was consi-
dered valid only if a complete hoof print of at least one
forelimb was recorded while the velocity was within a
preset range. Each measuring session was limited to the
number of trials necessary to obtain five valid measu-
rements of both forelimbs. The following kinetic vari-
ables were calculated for both forelimbs at the walk and
at the trot, and expressed as % symmetry (left/right x
100%): (1) peak vertical force (PVF), i.e. the maximal
vertical force value throughout the stance phase; (2)
vertical impulse (VI), calculated by time integration of
the force-time curves and (3) load rate (LR) of the ver-
tical force curve.
The peak vertical force (PVF), vertical impulse
(VI) and load rate (LR) symmetry ratios at all time
points are presented in Figure 3. Already after the first
injection with the autologous PB-derived MSC, an
increase of the LR symmetry ratio was observed in
both the walk and the trot, which even further increa-
sed considerably after the second injection (Figure 3).
Clear improvements were also seen in the PVF and VI
symmetry ratios, although these effects were more
pronounced at the trot than at the walk (Figure 3).
Medical imaging
Routine dorsopalmar and lateromedial radiographic
evaluation of the pastern joint did not reveal considera-
ble changes after the autologous MSC therapy compa-
red to pre-treatment radiographs (data not shown). Four
weeks before stem cell therapy, an ultrasonographic
examination was performed and did not show any ab-
normalities. Therefore, no further ultrasonography was
performed.
DISCUSSION
Mesenchymal stem cells represent a very promising
therapeutic tool for certain types of degenerative or
traumatic diseases in different animal species, because
Figure 2. Timeline of equine mesenchymal stem cells (MSC) injections and evaluation intervals. A 5-year-old stallion
with chronic lameness attributable to degenerative joint disease of the pastern joint was treated with autologous pe-
ripheral blood-derived MSC. Clinical evaluations and pressure plate analyses were performed 4 weeks before (T-1) and
at 4-week-intervals (T1= 4 weeks, T2= 8 weeks, T3= 12 weeks and T4= 16 weeks) after the first injection. P = passage.
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of their enormous plasticity and differentiation capa-
cities. The in vivo use of MSC in equine veterinary me-
dicine has been studied intensively, with several inde-
pendent studies reporting regenerative effects, mainly
in tendon and ligament injuries (Crovace et al. 2007;
Smith 2008). Equine degenerative joint disease is one
of the most common causes of early retirement and re-
formation of sport horses, and therefore, the use of
MSC is currently being explored for its regenerative
potential in this musculoskeletal injury (Berg et al.
2009; Koch and Betts 2007). To the knowledge of the
authors, there are only reports on the in vivo use of
equine adipose tissue (AT)-derived and bone marrow
(BM)-derived MSC for the treatment of osteoarthritis
(Frisbie et al. 2009; Wilke et al. 2007). In these studies,
osteoarthritis was experimentally induced and the MSC
were injected in the acute phase of the lesion (within
14 days). A short-term clinical improvement was noti-
ced after MSC therapy, although this was not the case
for the long-term follow-up of the horses. In contrast,
a more recent study by McIlwraith showed no evidence
of any clinically significant improvement in the joints
injected with BM-MSC, but arthroscopic evaluation
confirmed a significant increase in aggrecan produc-
tion, repair tissue firmness and a trend for better over-
all repair tissue quality in BM-MSC-treated joints.
(McIlwraith et al. 2011). This latter study emphasizes
the importance of combining clinical evaluation with
more scientifically-based parameters to evaluate the ef-
ficacy of MSC treatment in horses.
In the present case report, the authors describe for
the first time the use of peripheral blood (PB)-derived
MSC to treat a horse suffering from chronic lameness
attributable to DJD of the pastern joint. A positive res-
ponse to the therapy could already be demonstrated
four weeks after the first injection, as assessed by the
clinical evaluations and pressure plate analyses. For the
latter, it was proven that the load rate (LR) symmetry
ratio increased considerably in both gaits, indicating an
increased speed of loading at the walk as well as at the
trot. Moreover, a clear improvement in peak vertical
force (PVF) and vertical impulse (VI) symmetry ratios
was evident at the trot, indicating an increased sym-
metry of the weight-bearing function of the forelimbs.
The lack of an overall increasing improvement in PVF
and VI symmetry ratios at the walk is most likely as-
sociated with a lower reproducibility of the pressure
plate analysis at the walk than at the trot, as previou-
sly reported (Oosterlinck et al. 2010a). Currently, i.e.
one year after the MSC treatment, the stallion is not sho-
wing any signs of recurrent lameness and he is compe-
ting again (personal communication with the horse ow-
ner). Still, in order to truly confirm the effectiveness of
PB-MSC, a double blinded standardized model should
have been used with exactly the same induced lesions in
a large number of horses, including control groups.
Moreover, and in analogy to previously performed ex-
periments in horses where the fate of injected BM-MSC
was studied in an equine tendon injury model (Guest et
al. 2010), fluorescently-labelled PB-MSC could be used
to prove whether the in vivo cartilage regeneration is at-
tributable to the MSC itself or rather to the products they
secrete.
In conclusion, this case report is the first to describe
the successful treatment of a patient suffering from
chronic lameness attributable to DJD using autologous
PB-derived MSC. It is clear that this single case study
does not allow to draw definite conclusions on the cli-
nical efficacy of the treatment protocol, nor does it al-
low for an extrapolation to other equine pathologies
beyond DJD. However, the results of this case report are
encouraging to further evaluate the efficacy of autolo-
gous PB-derived MSC in equine regenerative medicine.
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Figure 3. Pressure plate analyses at the walk and the trot.
The patient was evaluated 4 weeks before (T-1) and at 4-
week-intervals (T1= 4 weeks, T2= 8 weeks, T3= 12 weeks and
T4= 16 weeks) after the first injection with autologous pe-
ripheral blood-derived mesenchymal stem cells (MSC) .
The following parameters were measured: peak vertical
force (PVF), vertical impulse (VI) and load rate (LR).
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